Damora Therapeutics, Inc. Common Stock (DMRA) Competitors

$25.02 +0.87 (+3.60%)

As of 01:31 PM Eastern

DMRA vs. COGT, SRRK, XENE, GRFS, and APLS

Should you buy Damora Therapeutics, Inc. Common Stock stock or one of its competitors? MarketBeat compares Damora Therapeutics, Inc. Common Stock with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Damora Therapeutics, Inc. Common Stock include Cogent Biosciences (COGT), Scholar Rock (SRRK), Xenon Pharmaceuticals (XENE), Grifols (GRFS), and Apellis Pharmaceuticals (APLS). These companies are all part of the "pharmaceutical products" industry.

How does Damora Therapeutics, Inc. Common Stock compare to Cogent Biosciences?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) and Cogent Biosciences (NASDAQ:COGT) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

14.2% of Damora Therapeutics, Inc. Common Stock shares are held by institutional investors. 0.4% of Damora Therapeutics, Inc. Common Stock shares are held by company insiders. Comparatively, 7.3% of Cogent Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Damora Therapeutics, Inc. Common Stock has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.37, indicating that its share price is 63% less volatile than the broader market.

In the previous week, Damora Therapeutics, Inc. Common Stock had 1 more articles in the media than Cogent Biosciences. MarketBeat recorded 1 mentions for Damora Therapeutics, Inc. Common Stock and 0 mentions for Cogent Biosciences. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 0.00 equaled Cogent Biosciences'average media sentiment score.

Company	Overall Sentiment
Damora Therapeutics, Inc. Common Stock	Neutral
Cogent Biosciences	Neutral

Damora Therapeutics, Inc. Common Stock currently has a consensus price target of $43.40, suggesting a potential upside of 73.46%. Cogent Biosciences has a consensus price target of $43.73, suggesting a potential upside of 32.95%. Given Damora Therapeutics, Inc. Common Stock's stronger consensus rating and higher possible upside, research analysts plainly believe Damora Therapeutics, Inc. Common Stock is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86

Cogent Biosciences is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$6.88	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A

Cogent Biosciences' return on equity of -104.27% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Damora Therapeutics, Inc. Common Stock	N/A	-428.30%	-114.62%
Cogent Biosciences	N/A	-104.27%	-54.64%

Summary

Damora Therapeutics, Inc. Common Stock beats Cogent Biosciences on 7 of the 12 factors compared between the two stocks.

How does Damora Therapeutics, Inc. Common Stock compare to Scholar Rock?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

14.2% of Damora Therapeutics, Inc. Common Stock shares are held by institutional investors. Comparatively, 91.1% of Scholar Rock shares are held by institutional investors. 0.4% of Damora Therapeutics, Inc. Common Stock shares are held by insiders. Comparatively, 13.3% of Scholar Rock shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Scholar Rock is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$6.88	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A

In the previous week, Scholar Rock had 8 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 9 mentions for Scholar Rock and 1 mentions for Damora Therapeutics, Inc. Common Stock. Scholar Rock's average media sentiment score of 0.59 beat Damora Therapeutics, Inc. Common Stock's score of 0.00 indicating that Scholar Rock is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Damora Therapeutics, Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Scholar Rock	3 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Scholar Rock's return on equity of -163.52% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Damora Therapeutics, Inc. Common Stock	N/A	-428.30%	-114.62%
Scholar Rock	N/A	-163.52%	-96.67%

Damora Therapeutics, Inc. Common Stock currently has a consensus target price of $43.40, indicating a potential upside of 73.46%. Scholar Rock has a consensus target price of $56.00, indicating a potential upside of 17.82%. Given Damora Therapeutics, Inc. Common Stock's higher possible upside, research analysts plainly believe Damora Therapeutics, Inc. Common Stock is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	5 Strong Buy rating(s)	3.17

Damora Therapeutics, Inc. Common Stock has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market.

Summary

Scholar Rock beats Damora Therapeutics, Inc. Common Stock on 10 of the 14 factors compared between the two stocks.

How does Damora Therapeutics, Inc. Common Stock compare to Xenon Pharmaceuticals?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) and Xenon Pharmaceuticals (NASDAQ:XENE) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

14.2% of Damora Therapeutics, Inc. Common Stock shares are held by institutional investors. Comparatively, 95.5% of Xenon Pharmaceuticals shares are held by institutional investors. 0.4% of Damora Therapeutics, Inc. Common Stock shares are held by insiders. Comparatively, 4.1% of Xenon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Damora Therapeutics, Inc. Common Stock has a beta of 1.5, meaning that its share price is 50% more volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market.

Damora Therapeutics, Inc. Common Stock currently has a consensus price target of $43.40, indicating a potential upside of 73.46%. Xenon Pharmaceuticals has a consensus price target of $77.07, indicating a potential upside of 40.90%. Given Damora Therapeutics, Inc. Common Stock's higher probable upside, analysts plainly believe Damora Therapeutics, Inc. Common Stock is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Xenon Pharmaceuticals had 2 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 3 mentions for Xenon Pharmaceuticals and 1 mentions for Damora Therapeutics, Inc. Common Stock. Xenon Pharmaceuticals' average media sentiment score of 0.77 beat Damora Therapeutics, Inc. Common Stock's score of 0.00 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Damora Therapeutics, Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xenon Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xenon Pharmaceuticals' return on equity of -49.23% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Damora Therapeutics, Inc. Common Stock	N/A	-428.30%	-114.62%
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%

Damora Therapeutics, Inc. Common Stock has higher earnings, but lower revenue than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$6.88	N/A
Xenon Pharmaceuticals	$7.50M	705.01	-$345.91M	-$4.70	N/A

Summary

Xenon Pharmaceuticals beats Damora Therapeutics, Inc. Common Stock on 10 of the 14 factors compared between the two stocks.

How does Damora Therapeutics, Inc. Common Stock compare to Grifols?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment.

14.2% of Damora Therapeutics, Inc. Common Stock shares are owned by institutional investors. 0.4% of Damora Therapeutics, Inc. Common Stock shares are owned by company insiders. Comparatively, 0.2% of Grifols shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Damora Therapeutics, Inc. Common Stock has a beta of 1.5, suggesting that its share price is 50% more volatile than the broader market. Comparatively, Grifols has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market.

Grifols has a net margin of 5.54% compared to Damora Therapeutics, Inc. Common Stock's net margin of 0.00%. Grifols' return on equity of 6.21% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Damora Therapeutics, Inc. Common Stock	N/A	-428.30%	-114.62%
Grifols	5.54%	6.21%	2.39%

Grifols has higher revenue and earnings than Damora Therapeutics, Inc. Common Stock. Damora Therapeutics, Inc. Common Stock is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$6.88	N/A
Grifols	$8.51B	0.65	$454.82M	$0.19	42.82

Damora Therapeutics, Inc. Common Stock presently has a consensus price target of $43.40, indicating a potential upside of 73.46%. Grifols has a consensus price target of $10.00, indicating a potential upside of 22.93%. Given Damora Therapeutics, Inc. Common Stock's stronger consensus rating and higher possible upside, equities research analysts plainly believe Damora Therapeutics, Inc. Common Stock is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
Grifols	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

In the previous week, Grifols had 1 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 2 mentions for Grifols and 1 mentions for Damora Therapeutics, Inc. Common Stock. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 0.00 beat Grifols' score of -0.17 indicating that Damora Therapeutics, Inc. Common Stock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Damora Therapeutics, Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Grifols	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Damora Therapeutics, Inc. Common Stock and Grifols tied by winning 8 of the 16 factors compared between the two stocks.

How does Damora Therapeutics, Inc. Common Stock compare to Apellis Pharmaceuticals?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk and dividends.

14.2% of Damora Therapeutics, Inc. Common Stock shares are owned by institutional investors. Comparatively, 96.3% of Apellis Pharmaceuticals shares are owned by institutional investors. 0.4% of Damora Therapeutics, Inc. Common Stock shares are owned by insiders. Comparatively, 6.5% of Apellis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Apellis Pharmaceuticals has a net margin of 12.06% compared to Damora Therapeutics, Inc. Common Stock's net margin of 0.00%. Apellis Pharmaceuticals' return on equity of 39.71% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Damora Therapeutics, Inc. Common Stock	N/A	-428.30%	-114.62%
Apellis Pharmaceuticals	12.06%	39.71%	13.20%

Damora Therapeutics, Inc. Common Stock has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market. Comparatively, Apellis Pharmaceuticals has a beta of -0.24, indicating that its share price is 124% less volatile than the broader market.

In the previous week, Apellis Pharmaceuticals had 5 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 6 mentions for Apellis Pharmaceuticals and 1 mentions for Damora Therapeutics, Inc. Common Stock. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 0.00 equaled Apellis Pharmaceuticals'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Damora Therapeutics, Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Apellis Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Apellis Pharmaceuticals has higher revenue and earnings than Damora Therapeutics, Inc. Common Stock. Damora Therapeutics, Inc. Common Stock is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$6.88	N/A
Apellis Pharmaceuticals	$1.11B	4.75	$22.39M	$1.02	40.23

Damora Therapeutics, Inc. Common Stock currently has a consensus price target of $43.40, suggesting a potential upside of 73.46%. Apellis Pharmaceuticals has a consensus price target of $35.72, suggesting a potential downside of 12.94%. Given Damora Therapeutics, Inc. Common Stock's stronger consensus rating and higher possible upside, research analysts clearly believe Damora Therapeutics, Inc. Common Stock is more favorable than Apellis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
Apellis Pharmaceuticals	1 Sell rating(s)	18 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.09

Summary

Apellis Pharmaceuticals beats Damora Therapeutics, Inc. Common Stock on 10 of the 15 factors compared between the two stocks.

Get Damora Therapeutics, Inc. Common Stock News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DMRA vs. The Competition

Export

Metric	Damora Therapeutics, Inc. Common Stock	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.54B	$3.33B	$6.30B	$12.21B
Dividend Yield	N/A	2.32%	2.80%	5.36%
P/E Ratio	-3.64	18.72	20.79	25.32
Price / Sales	N/A	274.99	518.79	71.95
Price / Cash	N/A	125.35	43.18	55.00
Price / Book	4.06	6.82	9.96	6.97
Net Income	-$209.84M	$24.18M	$3.54B	$334.92M
7 Day Performance	4.77%	-0.32%	-0.19%	-0.98%
1 Month Performance	-6.71%	-1.41%	-0.63%	0.43%
1 Year Performance	741.01%	61.67%	34.10%	33.61%

Damora Therapeutics, Inc. Common Stock Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DMRA Damora Therapeutics, Inc. Common Stock	1.6606 of 5 stars	$25.02 +3.6%	$43.40 +73.5%	+689.2%	$1.54B	N/A	N/A	40
COGT Cogent Biosciences	2.2482 of 5 stars	$34.53 +1.3%	$43.73 +26.6%	+520.0%	$5.83B	N/A	N/A	80
SRRK Scholar Rock	2.7079 of 5 stars	$49.19 +1.7%	$56.00 +13.8%	+53.4%	$5.79B	N/A	N/A	140
XENE Xenon Pharmaceuticals	3.6075 of 5 stars	$55.00 -1.4%	$75.69 +37.6%	+74.0%	$5.39B	$7.50M	N/A	210	Positive News
GRFS Grifols	4.1632 of 5 stars	$7.56 -3.1%	$10.00 +32.3%	+1.9%	$5.31B	$8.51B	39.79	25,247	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DMRA) was last updated on 5/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Damora Therapeutics, Inc. Common Stock (DMRA) Competitors

DMRA vs. COGT, SRRK, XENE, GRFS, and APLS

How does Damora Therapeutics, Inc. Common Stock compare to Cogent Biosciences?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Scholar Rock?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Xenon Pharmaceuticals?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Grifols?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Apellis Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMRA vs. The Competition

Damora Therapeutics, Inc. Common Stock Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Damora Therapeutics, Inc. Common Stock (DMRA) Competitors

DMRA vs. COGT, SRRK, XENE, GRFS, and APLS

How does Damora Therapeutics, Inc. Common Stock compare to Cogent Biosciences?

Do insiders & institutionals believe in DMRA or COGT?

Which has more volatility and risk, DMRA or COGT?

Does the media refer more to DMRA or COGT?

Do analysts rate DMRA or COGT?

Which has better earnings & valuation, DMRA or COGT?

Is DMRA or COGT more profitable?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Scholar Rock?

Do insiders and institutionals believe in DMRA or SRRK?

Which has higher valuation & earnings, DMRA or SRRK?

Does the media refer more to DMRA or SRRK?

Is DMRA or SRRK more profitable?

Do analysts rate DMRA or SRRK?

Which has more risk & volatility, DMRA or SRRK?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Xenon Pharmaceuticals?

Do insiders and institutionals have more ownership in DMRA or XENE?

Which has more risk & volatility, DMRA or XENE?

Do analysts recommend DMRA or XENE?

Does the media favor DMRA or XENE?

Is DMRA or XENE more profitable?

Which has preferable earnings and valuation, DMRA or XENE?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Grifols?

Do institutionals and insiders have more ownership in DMRA or GRFS?

Which has more volatility & risk, DMRA or GRFS?

Is DMRA or GRFS more profitable?

Which has higher earnings and valuation, DMRA or GRFS?

Do analysts rate DMRA or GRFS?

Does the media refer more to DMRA or GRFS?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Apellis Pharmaceuticals?

Do insiders & institutionals hold more shares of DMRA or APLS?

Is DMRA or APLS more profitable?

Which has more volatility and risk, DMRA or APLS?

Does the media prefer DMRA or APLS?

Which has stronger earnings and valuation, DMRA or APLS?

Do analysts rate DMRA or APLS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMRA vs. The Competition

Damora Therapeutics, Inc. Common Stock Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools